Robbins LLP is Investigating Allegations that EyePoint, Inc. Misled Investors About the Efficacy and Viability of DURAVYU for the Treatment of Wet Age-Related Macular Degeneration
Robbins LLP informs investors that a class action was filed on behalf of all persons who purchased or otherwise acquired EyePoint, Inc. (NASDAQ: EYPT) securities between May 27, 2025 and August 14, 2026, both dates inclusive (the “Class Period”). EyePoint develops and commercializes therapeutics to purportedly improve the lives of patients with serious retinal diseases.
Why Was EyePoint, Inc. Sued?
According to the complaint, during the Class Period, defendants were evaluating DURAVYU for the treatment of wet age-related macular degeneration (“wet AMD”) in EyePoint’s Phase 3 LUGANO and LUCIA trials. The primary endpoint of both trials was the average change in best corrected visual acuity (“BCVA”) at weeks 52 and 56 versus baseline.
Plaintiff alleges that defendants touted DURAVYU’s purportedly “differentiated profile,” as well as its “uniquely suited” mechanism of action and “robust” and “best-in-class” efficacy profile, purportedly demonstrated by data from other studies.
While making these positive statements, plaintiff contends that defendants failed to disclose that DURAVYU was less effective than defendants had led investors to believe and accordingly, DURAVYU’s clinical, regulatory, and commercial prospects were overstated.
Why Did EyePoint’s Stock Drop?
Plaintiff alleges that the truth began to emerge on August 17, 2026, when EyePoint issued a press release announcing topline results from the LUGANO trial. The press release disclosed, in relevant part, that “the primary endpoint of change from baseline in best corrected visual acuity (BCVA) versus 2 mg aflibercept on-label control was not achieved in the full dataset, confounded by [an] asymmetric cohort.” On this news, EyePoint’s stock price fell $9.88 per share, or 66.98%, to close at $4.87 per share on August 17, 2026.
Then, on October 19, 2026, EyePoint’s stock fell $2.55 per share, or 85.28%, to close at $0.44 per share, following the release of disappointing topline results from the LUCIA trial and the announcement that the Company was terminating its late-stage wet AMD clinical program and reducing its workforce by 53%.
Who May Be Eligible to Participate in the EyePoint, Inc. Class Action?
The lawsuit seeks to represent investors who purchased or otherwise acquired EyePoint, Inc. securities between May 27, 2025 and August 14, 2026. Investors who suffered losses during that period may have legal rights under the federal securities laws. Submit a form for information.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.





